Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. The session is scheduled for Thursday, September 10, 2026, at 12:45 p.m. ET and will be accessible via the Investors “News & Events” page on the company’s website.
Details
News Market Reaction – MGX
On Sep 1, the day this news came out, MGX closed 1.27% below the previous close.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Conference edition
- 21st annual
- Wells Fargo Healthcare Conference
- Presentation date
- September 10, 2026
- Fireside chat
- Presentation time
- 12:45 p.m. ET
- September 10, 2026
Historical Context
-
Net loss widened while collaboration revenue turned negative during the quarter.
-
CEO participation in a fireside chat preceded a 3.7% 24-hour gain.
-
Quarterly results and pipeline updates were followed by no 24-hour price change.
-
Publication reported enhanced compact nuclease editing efficiency without a recorded price change.
-
Pipeline progress and cash runway updates preceded an 8.07% 24-hour decline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
in vivo genome editing technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, being held in Boston, MA, on Thursday, September 10, 2026, at 12:45 p.m. ET.
The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.